Waugh, Norman, Cummins, E. (Ewen), Royle, Pamela, Clar, C., Marien, M., Richter, B. and Philip, S.. (2010) Newer agents for blood glucose control in type 2 diabetes : systematic review and economic evaluation. Health Technology Assessment, Vol.14 (No.36). pp. 1-248. ISSN 1366-5278

Preview	Text (Coversheet) WRAP_Waugh_Newer_agents_blood_coversheet.pdf - Supplemental Material Download (49Kb) | Preview
Preview	Text WRAP_Waugh_Newer_agents_blood.pdf - Published Version Download (1880Kb) | Preview

Abstract

Exenatide, the gliptins and detemir were all clinically effective. The long-acting insulin analogues glargine and detemir appeared to have only slight clinical advantages over NPH, but had much higher costs and did not appear to be cost-effective as first-line insulins for type 2 diabetes. Neither did exenatide appear to be cost-effective compared with NPH but, when used as third drug after failure of dual oral combination therapy, exenatide appeared cost-effective relative to glargine in this analysis. The gliptins are similar to the glitazones in glycaemic control and costs, and appeared to have fewer long-term side effects. Therefore, it appears, as supported by recent NICE guidelines, that NPH should be the preferred first-line insulin for the treatment of type 2 diabetes. More economic analysis is required to establish when it becomes cost-effective to switch from NPH to a long-acting analogue. Also, long-term follow-up studies of exenatide and the gliptins, and data on combined insulin and exenatide treatment, would be useful.

Item Type:	Journal Article
Subjects:	R Medicine > RC Internal medicine
Divisions:	Faculty of Medicine > Warwick Medical School > Health Sciences
Library of Congress Subject Headings (LCSH):	Non-insulin-dependent diabetes -- Treatment
Journal or Publication Title:	Health Technology Assessment
Publisher:	Health Technology
ISSN:	1366-5278
Date:	July 2010
Volume:	Vol.14
Number:	No.36
Page Range:	pp. 1-248
Status:	Peer Reviewed
Publication Status:	Published
Access rights to Published version:	Open Access
Funder:	NIHR Health Technology Assessment Programme (Great Britain)
Grant number:	08/05/01 (NIHR HTA)
References:	1. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999;131:281– 303. 2. UKPDS Study Group. UK Prospective Diabetes Study. V. Characteristics of newly presenting type 2 diabetic patients: estimated insulin sensitivity and islet 4-cell function. Multi-centre study. Diabet Med 1988;5:444–8. 3. UKPDS Study Group. UK Prospective Diabetes Study. IV. Characteristics of newly presenting type 2 diabetic patients: male preponderance and obesity at different ages. Multi-centre study. Diabet Med 1988;5:154–9. 4. UKPDS Study Group. UK Prospective Diabetes Study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. UK Prospective Diabetes Study Group. Diabetes 1995;44:1249–58. 5. Turner R, Cull C, Holman R. UK Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996;124:136–45. 6. National Institute for Health and Clinical Excellence (NICE). Type 2 diabetes: the management of type 2 diabetes (update). Clinical Guideline CG66; May 2008. URL: www.nice.org.uk/Guidance/CG66 (accessed 25 September 2008). 7. Black C, Donnelly P, McIntyre L, Royle PL, Shepherd JP, Thomas S. Meglitinide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007;1:CD004654. 8. Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005;3:CD002966. 9. Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2006;CD002967. [Updated in Cochrane Database Syst Rev 2010;4:CD002967.] 10. Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, Rutten GE, Van WC. Alphaglucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005;2:CD003639. 11. The Information Centre and Yorkshire and Humber Public Health Observatory (YHPHO). Prescribing for Diabetes in England: an analysis of volume, expenditure and trends; 2007. URL: www.yhpho.org. uk/Download/Public/1265/1/Prescribing%20for%20 Diabetes%20in%20England%20Nov%202007%20 FINAL.pdf (accessed 4 May 2008). 12. National Insitute for Health and Clinical Excellence (NICE) Guidance on the use of long-acting insulin analogues for the treatment of diabetes – insulin glargine: Technology Appraisal 53; 2002. URL: www.nice. org.uk/nicemedia/pdf/53_Insulin_analogues_full_ guidance.pdf (accessed 4 May 2008). 13. Calvert MJ, McManus RJ, Freemantle N. Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study. Br J Gen Pract 2007;57:455–60. 14. Rubino A, McQuay LJ, Gough SC, Kvasz M, Tennis P. Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with type 2 diabetes: a population-based analysis in the UK. Diabet Med 2007;24:1412–18. 15. Black C, Cummins E, Royle P, Philip S, Waugh N. The clinical effectiveness and cost-effectiveness of inhaled insulin in diabetes mellitus: a systematic review and economic evaluation. Health Technol Assess 2007;11(33). 16. Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005;28:2673–9. 17. Alvarez GF, Mavros P, Nocea G, Alemao E, Alexander CM, Yin D. Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real- Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study. Diabetes Obes Metab 2008;10(Suppl. 1):8–15. 18. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006;49:1711–21. 19. Goudswaard AN, Furlong NJ, Rutten GE, Stolk RP, Valk GD. Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. Cochrane Database Syst Rev 2004;4:CD003418. 20. Douek IF, Allen SE, Ewings P, Gale EA, Bingley PJ. Continuing metformin when starting insulin in patients with Type 2 diabetes: a double-blind randomized placebo-controlled trial. Diabet Med 2005;22:634–40. 21. Aviles-Santa L, Sinding J, Raskin P. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999;131:182–8. 22. Strowig SM, Raskin P. Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus. Diabetes Obes Metab 2005;7:633–41. 23. Bailey CJ. Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones. Diabetes Obes Metab 2005;7:675–91. 24. Gerstein HC, Yale JF, Harris SB, Issa M, Stewart JA, Dempsey E. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucoselowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med 2006;23:736–42. 25. Hayward RA, Manning WG, Kaplan SH, Wagner EH, Greenfield S. Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization. JAMA 1997;278:1663–9. 26. Yki-Järvinen H, Kauppinen-Makelin R, Tiikkainen M, Vahatalo M, Virtamo H, Nikkila K, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006;49:442–51. 27. Aas AM, Bergstad I, Thorsby PM, Johannesen O, Solberg M, Birkeland KI. An intensified lifestyle intervention programme may be superior to insulin treatment in poorly controlled type 2 diabetic patients on oral hypoglycaemic agents: results of a feasibility study. Diabet Med 2005;22:316–22. 28. Aas AM, Seljeflot I, Torjesen PA, Diep LM, Thorsby PM, Birkeland KI. Blood glucose lowering by means of lifestyle intervention has different effects on adipokines as compared with insulin treatment in subjects with type 2 diabetes. Diabetologia 2006;49:872–80. 29. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427–43. 30. Aston-Mourney K, Proietto J, Morahan G, Andrikopoulos S. Too much of a good thing: why it is bad to stimulate the beta cell to secrete insulin. Diabetologia 2008;51:540–5. 31. Meier JJ. Beta cell mass in diabetes: a realistic therapeutic target? Diabetologia 2008;51:703–13. 32. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007;298:194–206. 33. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131–57. 34. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7–36: a physiological incretin in man. Lancet 1987;2:1300–4. 35. Meier S, Hucking K, Ritzel R, Holst JJ, Schmiegel WH, Nauck MA. Absence of a memory effect for the insulinotropic action of glucagon-like peptide 1 (GLP-1) in healthy volunteers. Horm Metab Res 2003;35:551–6. 36. Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A 1987;84:3434–8. 37. Fehmann HC, Habener JF. Insulinotropic glucagonlike peptide-I(7–37)/(7–36)amide: a new incretin hormone. Trends Endocrinol Metab 1992;3:158–63. 38. Barnett A. Exenatide. Expert Opin Pharmacother 2007;8:2593–608. 39. Nauck MA, Walberg J, Vethacke A, El-Ouaghlidi A, Senkal M, Holst JJ, et al. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1. Regul Pept 2004;118:89–97. 40. Deacon CF. Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab 2007;9(Suppl. 1):23–31. 41. Nauck MA, Wollschlager D, Werner J, Holst JJ, Orskov C, Creutzfeldt W, et al. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7–36 amide]) in patients with NIDDM. Diabetologia 1996;39:1546–53. 42. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008;24:275–86. 43. European Medicines Agency. Byetta: European Public Assessment Report. 7 January 2009. URL: www.emea.europa.eu/humandocs/Humans/EPAR/ byetta/byetta.htm (accessed 25 March 2009). 44. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359:824–30. 45. Amylin Pharmaceuticals. 2008. URL: www.amylin. com/ (accessed 2 June 2009). 46. Eli Lilly and Company. 2008. URL: www.lilly.co.uk/ (accessed 2 June 2009). 47. Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, et al. Effects of onceweekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007;30:1487–93. 48. Novo Nordisk. 2008. URL: www.novonordisk.com/ (accessed 2 June 2009). 49. FDA. Byetta (Exenatide injection); 2005. URL: www.fda.gov/cder/foi/label/2008/021773s012lbl.pdf (accessed 4 May 2008). 50. Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, twoperiod, crossover noninferiority trial. Clin Ther 2007;29:2333–48. 51. Seino Y, Kaku K, Nishijima K, Rasmussen MF, Zdravkovic M, Kristensen P. The long-acting human GLP-1 analogue liraglutide given once daily significantly improves glycaemic control by reducing fasting and postprandial glucose levels in subjects of Japanese origin with type 2 diabetes. Diabetologia 2007;50:S352. 52. Davis SN, Johns D, Maggs D, Xu H, Northrup JH, Brodows RG. Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. Diabetes Care 2007;30:2767–72. 53. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: A randomized trial. Ann Intern Med 2005;143:559–69. 54. Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007;50:259–67. 55. Bunck MC, Diamant M, Corner A, Eliasson B, Malloy JL, Shaginian RM, et al. One year treatment with exenatide improves beta cell function and glycaemic control in metformin treated type 2 diabetes patients. Diabetologia 2007;50:S111–12. 56. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylureatreated patients with type 2 diabetes. Diabetes Care 2004;27:2628–35. 57. Trescoli-Serrano C, Rivas M, Fajardo-Montanana C, Del Pino I, Garcia-Zarco M, Martorrell-Barraquet A, et al. Clinical site experience comparing insulin glargine with exenatide treatment in type 2 diabetic patients. Diabetologia 2005;48:A3. 58. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2. Diabetes Care 2005;28:1092–100. 59. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083–91. 60. Zinman B, Hoogwerf BJ, Duran GS, Milton DR, Giaconia JM, Kim DD, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007;146:477–85. 61. Malozowski S. Exenatide in combination therapy: small study, big market, and many unanswered questions. Ann Intern Med 2007;146:527–8. 62. Home PD. Comment on: A comparison of twicedaily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study [Nauck MA, Duran S, Kim D, et al. (2007), Diabetologia 50:259–67]. Diabetologia 2007;50:1561–2. 63. Nauck MA, Trautman M, Brodows R, Johns D, Northrup J, Kim D. Response to comment on: A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study [Nauck MA, Duran S, Kim D, et al. (2007), Diabetologia 50:259– 67]. Diabetologia 2007;50:1563–4. 64. Rosenstock J, Fonseca V. Missing the point: substituting exenatide for nonoptimized insulin: going from bad to worse! Diabetes Care 2007;30:2972–3. 65. Maggs D, Kim D, Holcombe J, Han J, Shen L, Ruggles J, et al. Exenatide-induced reductions in A1C and body weight in long-term trials are not explained by gastrointestinal side effects. Diabetes 2005;54:A120. 66. Secnik K, Oglesby A, Yurgin N, Johns D, Trautman M. Exenatide compared with insulin glargine: patient reported outcomes assessments in individuals with type 2 diabetes. Poster presented at IDF meeting, Cape Town, South Africa, 3–7 December 2006. 67. Secnik BK, Matza LS, Oglesby A, Malley K, Kim S, Hayes RP, et al. Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes. Health Qual Life Outcomes 2006;4:80. 68. Yurgin N, Secnik K, Hayes C, Johns D, Trautmann M. Patient reported outcomes in patients with type 2 diabetes treated with exenatide compared to biphasic insulin aspart. Diabetologia 2006;49:474–5. 69. Wolfe G, King A. Lack of continued weight loss beyond six months despite continued exenatide (EX) treatment. Diabetes 2007;56:A548. 70. Loh JA, Clement SC. Efficacy of exenatide therapy over 12 months in a ‘real world’ setting. Diabetes 2007;56:A152. 71. Yoon N, Cavaghan MK, Brunelle R, Roach P. Exenatide added to insulin therapy: clinical experience in an academic endocrinology. Diabetes 2008;57:A144. 72. Bhushan R, Elkind-Hirsh KE, Bhushan M, Butler WJ, Duncan KD, Marionneaux O. Effects of exenatide therapy in patients with type 2 diabetes include reductions in HbA1c, weight, and cardiovascular risk factors in routine clinical practice. Diabetes 2008;57:A571. 73. Govindan JP, Healey B, Kalupahana DN, Singh BM. Exenatide therapy in insulin treated patients with type 2 diabetes and obesity. Diabetologia 2008;51:S352–3. 74. Wintle M, Fabunmi R, Boye K, Adam-Marx C, Ye X, Brixner D. Real-world six-month outcomes of patients initiating exenatide in a primary care electronic medical record database. Diabetologia 2008;51:S352. 75. Kendall D, Nielsen L, Han J, Brodows R, Bhole D. Metabolic improvement associated with temporal pattern of weight loss in exenatide-treated patients with type 2 diabetes. Diabetologia 2008;51:S353–4. 76. Drucker DJ, Buse JB, Taylor K, Kendall D, Trautmann M, Zhuang DL, et al. Exenatide once weekly results in significantly greater improvements in glycemic control compared to exenatide twice daily in patients with type 2 diabetes. Diabetes 2008;57:A33. 77. Buse J, Drucker D, Taylor K, Kim T, Wilhelm K, Kendall D, et al. Exenatide once weekly elicits sustained glycaemic control and weight loss over 52 weeks. Diabetologia 2008;51:S67. 78. Gallwitz B. Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data. Int J Clin Pract 2006;60:1654–61. 79. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999;48:2270–6. 80. Gedulin BR, Nikoulina SE, Smith PA, Gedulin G, Nielsen LL, Baron AD, et al. Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology 2005;146:2069–76. 81. Tourrel C, Bailbe D, Meile MJ, Kergoat M, Portha B. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocintreated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 2001;50:1562–70. 82. Holst JJ, Deacon CF, Vilsboll T, Krarup T, Madsbad S. Glucagon-like peptide-1, glucose homeostasis and diabetes. Trends Mol Med 2008;14:161–8. 83. Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007;28:187–218. 84. Bunck MC, Diamant M, Corner A, Eliasson B, Malloy JL, Shaginian RM, et al. beta-cell function and glycemic control following one year exenatide therapy, and after 12 week wash out, in patients with type 2 diabetes. Diabetes 2008;57:A32. 85. Bunck MC, Corner A, Diamant M, Eliasson B, Malloy JL, Shaginian RM, et al. Exenatide improves postprandial hyperglycemia and dyslipidemia in metformin treated patients with type 2 diabetes. Diabetes 2008;57:A33. 86. Exenatide: new drug. Type 2 diabetes for some overweight patients. Prescrire Int 2007;16:228–31. 87. Institute for Quality and Efficiency in Health Care (IQWIG). Evaluation of therapeutic benefits and harms of Exenatide; 2007. URL: www.iqwig.de/index.563. en.html (accessed 5 May 2008). 88. European Medicines Agency. Exenatide. Annex 1: Summary of Product Characteristics; 2008. URL: www. emea.europa.eu/humandocs/PDFs/EPAR/byetta/H- 698-PI-en.pdf (accessed 4 May 2008). 89. US Food and Drug Administration (FDA). FDA Drug Safety Newsletter. Volume 1, Number 2, Winter 2008. URL: www.fda.gov/cder/dsn/2008_winter/ postmarketing.htm (accessed 2 June 2009). 90. Medicines and Healthcare Products Regulatory Agency (MHRA). MHRA Drug Safety Update. Volume 1, Issue 10, May 2008. URL: www.mhra.gov.uk/ Publications/Safetyguidance/DrugSafetyUpdate/ CON015025 (accessed 25 September 2008). 91. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008;2:CD006739. 92. European Medicines Agency. EPARS for authorised medicinal products for human use. Onglyza; 2009. URL: www.ema.europa.eu/humandocs/Humans/EPAR/ onglyza/onglyza (accessed 4 March 2010). 93. US Food and Drug Administration (FDA). Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee, 10 March 2009. URL: www. fda.gov/cder/audiences/acspage/meetings/emdac_ meeting_20090402.htm (accessed 25 March 2009). 94. European Medicines Agency. EPARs for authorised medicinal products for human use; 2008. URL: www. emea.europa.eu/htms/human/epar/eparintro.htm (accessed 25 September 2008). 95. US Food and Drug Administration (FDA). 2008. URL: www.fda.gov/(accessed 19 April 2008). 96. Ahren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformintreated patients with type 2 diabetes. Diabetes Care 2004;27:2874–80. 97. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632–7. 98. Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007;30:890–5. 99. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638–43. 100. Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 2007;39:218–23. 101. Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007;50:1148–55. 102. Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007;9:166–74. 103. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30:1979–87. 104. Hanefeld M, Herman GA, Wu M, Mickel C, Sanchez M, Stein PP. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin 2007;23:1329–39. 105. Mimori N, Terao S, Holmes D. Vildagliptin improves glucose control as evidenced by HbA(1c) after 12 weeks therapy in Japanese patients with type 2 diabetes. Diabetes 2006;55:A125–6. 106. Nonaka K, Kakikawa T, Sato A, Okuyama K, Fujimoto G, Hayashi N, et al. Twelve-week efficacy and tolerability of sitagliptin, a dipleptidyl peptidase-IV (DPP4) inhibitor, in Japanese patients with T2DM. Diabetes 2006;55:A128. 107. Pan C, Yang W, Barona JP, Wang Y, Niggli M, Mohideen P, et al. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetic Med 2008;25:435–41. 108. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007;76:132–8. 109. Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 2006;38:423–8. 110. Raz I, Hanefeld M, Xu L, Caria C, Williams- Herman D, Khatami H, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006;49:2564–71. 111. Raz I, Chen Y, Wu M, Hussain S, Kaufman KD, Amatruda JM, et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin 2008;24:537–50. 112. Ristic S, Byiers S, Foley J, Holmes D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 2005;7:692–8. 113. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24- week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006;28:1556–68. 114. Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 2007;30:217–23. 115. Rosenstock J, Baron MA, Camisasca RP, Cressier F, Couturier A, Dejager S. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007;9:175–85. 116. Rosenstock J, Foley JE, Rendell M, Landin-Olsson M, Holst JJ, Deacon CF, et al. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care 2008;31:30–5. 117. Scherbaum WA, Schweizer A, Mari A, Nilsson PM, Lalanne G, Wang Y, et al. Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab 2008;10:1114–24. 118. Scherbaum WA, Schweizer A, Mari A, Nilsson PM, Lalanne G, Jauffret S, et al. Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab 2008;10:675–82. 119. Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drugnaive patients with Type 2 diabetes. Diabetic Med 2007;24:955–61. 120. Scott R, Wu M, Sanchez M, Stein P. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Prac 2007;61:171–80. 121. Scott R, Loeys T, Davies MJ, Engel SS. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2008;10:959–69. 122. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9:194–205. 123. Bolli G, Dotta F, Rochotte E, Cohen SE. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab 2008;10:82–90. 124. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007;9:733–45. 125. Williams-Herman D, Round E, Swern AS, Musser B, Davies MJ, Stein PP, et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocr Disord 2008;8:14. 126. Dobs A, Goldstein BJ, Wieczorek L, Golm G, Davies MJ, Williams-Herman D, et al. Triple combination therapy with sitagliptin, metformin, and rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes 2008;57:A595–6. 127. Hanefeld M, Herman G, Mickej C, McGowan A, Wu M, Zhao P, et al. Effect of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor, on glycemic control after 12 weeks in patients with type 2 diabetes. Diabetologia 2005;48:A287. 128. Nonaka K, Kakikawa T, Sato A, Okuyama K, Fujimoto G, Kato N, et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008;79:291–8. 129. Yang W, Mohan V, Son HY, Liu J, Langdon RB, Stein P. Sitagliptin monotherapy significantly improves glycaemic control and beta-cell function, and is well tolerated in patients with type 2 diabetes in China, India, and Korea. ASEAN Federation of Endocrine Societies 2007;24(Suppl. 1):90. 130. Green BD, Flatt PR, Bailey CJ. Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes. Diab Vasc Dis Res 2006;3:159–65. 131. British Medical Association and Royal Pharmaceutical Society of Great Britain. British national formulary. No. 55, March 2008. London: BMA and RPS; 2008. 132. Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 2005;90:501–6. 133. Krobot KJ, Stein PP, Allen S, Davies MJ, Meininger G. Lower risk of hypoglycemia with sitagliptin compared to glipizide when added to ongoing metformin therapy: an analysis based on A1Cadjusted event rates. Diabetes 2008;57:A607. 134. Goodman M, Thurston H, Minic B, Thuren T. Improved glycaemic control with vildagliptin 100 mg administered either as a morning or evening dose as add-on therapy to metformin in type 2 diabetes mellitus. Diabetologia 2008;51:S366. 135. Arjona-Ferreira JC, Dobs A, Goldstein BJ, Wieczorek L, Golm G, Davies MJ, et al. Triple combination therapy with sitagliptin, metformin, and rosiglitazone improves glycaemic control in patients with type 2 diabetes. Diabetologia 2008;51:S365. 136. Braceras R, Blonde L, Banerji M, Gogo-Jack S, Pratley R, Marcellari A, et al. Vildagliptin is as effective as TZDs in metformin failures: results of GALIANT – a primary care diabetes study. Diabetologia 2008;51:S366. 137. Yki-Järvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000;23: 1130–6. 138. Hennige AM, Sartorius T, Tschritter O, Preissl H, Fritsche A, Ruth P, et al. Tissue selectivity of insulin detemir action in vivo. Diabetologia 2006;49:1274– 82. 139. Hermansen K, Derezinski T, Kim H, Gall MA. Treatment with insulin detemir in combination with oral agents is associated with less risk of hypoglycaemia and less weight gain than NPH insulin at comparable levels of glycaemic improvement in people with Type 2 diabetes. Diabetologia 2004;47:A273–4. 140. Duckworth W, Davis SN. Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies. J Diab Complications 2007;21:196–204. 141. Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzer TW, Plank J, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.[see comment]. Cochrane Database Syst Rev 2007;2:CD005613. 142. Tran K, Banerjee S, Li H, Cimon K, Daneman D, Simpson SH. Short-acting insulin analogues for diabetes mellitus: meta-analysis of clinical outcomes and assessment of cost-effectiveness. The Canadian Agency for Drugs and Technologies in Health (CADTH), Ottawa; 2007. URL: http://cadth.ca/index.php/en/ publication/706 (accessed 2 June 2009). 143. Wang F. Insulin glargine: a systematic review of a long-acting insulin analogue. Clin Ther 2003;25:1541–77. 144. Warren E, Weatherley-Jones E, Chilcott J, Beverley C. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Technol Assess 2004;8(45). 145. Bazzano LA, Lee LJ, Shi L, Reynolds K, Jackson JA, Fonseca V. Safety and efficacy of glargine compared with NPH insulin for the treatment of Type&nbsp;2 diabetes: a meta-analysis of randomized controlled trials. Diabetic Med 2008;25:924–32. 146. Monami M, Marchionni N, Mannucci E. Longacting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract 2008;81:184–9. 147. Dailey G, Riddle M, Benedetti MM, Fritsche A, Lin ZN, Salzman A. A meta-analysis of phase III/IIIb studies comparing insulin glargine with human NPH insulin in type 2 diabetes: severe hypoglycemia is less common with glargine. Diabetes 2003;52:A444. 148. Garber AJ, Clauson P, Pedersen CB, Kolendorf K. Lower risk of hypoglycemia with insulin detemir than with neutral protamine hagedorn insulin in older persons with type 2 diabetes: a pooled analysis of phase III trials. J Am Geriatr Soc 2007;55: 1735–40. 149. Glass LC, Qu YM, Lenox S, Kim D, Gates JR, Brodows R, et al. Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis. Curr Med Res Opin 2008;24:639–44. 150. Hemraj F, Garces K. Insulin glargine for type 2 diabetes. Issues Emerg Health Technol 2004;8:1–4. 151. Mullins P, Sharplin P, Yki-Järvinen H, Riddle MC, Haring HU. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus. Clin Ther 2007;29:1607–19. 152. Mullins P, Jarvinen HY, Sharplin PA, Riddle M. Hypoglycemia and glycemic control in type 2 diabetes: a meta-analysis of six randomized controlled trials comparing insulin NPH with insulin glargine. Diabetes 2007;56:A160. 153. Rašlová K, Tamer SC, Clauson P, Karl D. Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index. Clin Drug Investig 2007;27:279– 85. 154. Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005;28:950–5. 155. Swinnen SGHA, Holleman F, DeVries JH, Hoekstra JBL. Long-acting insulin analogue versus another long-acting insulin analogue for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews: Protocols. Cochrane Database Syst Rev 2007;1:CD006383. 156. Fonseca V, Bell D, Mecca T. Less symptomatic hypoglycemia with insulin glargine compared to NPH in patients with type 2 diabetes. Diabetologia 2001;44:A207. 157. Fonseca V, Bell D, Mecca T. Less symptomatic hypoglycemia with bedtime insulin glargine (Lantus (R)) compared to bedtime NPH insulin in patients with type 2 diabetes. Diabetes 2001;50:A112. 158. Fonseca V, Bell DS, Berger S, Thomson S, Mecca TE. A comparison of bedtime insulin glargine with bedtime neutral protamine hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study. Am J Med Sci 2004;328:274–80. 159. Rosenstock J, Schwartz SL, Clark CM, Jr, Park GD, Donley DW, Edwards MB. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001;24:631–6. 160. Yokoyama H, Tada J, Kamikawa F, Kanno S, Yokota Y, Kuramitsu M. Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy. Diabetes Res Clin Pract 2006;73:35–40. 161. Eliaschewitz FG, Calvo C, Valbuena H, Ruiz M, Aschner P, Villena J, et al. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Arch Med Res 2006;37:495–501. 162. Fritsche A, Schweitzer MA, Haring HU. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 2003;138:952–9. 163. HOE 901 Study Investigators Group. Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in Type 2 diabetic patients. Diabet Med 2003;20:545–51. 164. Matthews DR, Pfeiffer C. Comparative clinical trial of a new long-acting insulin (HOE901) vs. protamine insulin demonstrates less nocturnal hypoglycaemia. Diabetes 1998;47:A101. 165. Massi Benedetti M, Humburg E, Dressler A, Ziemen M. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res 2003;35:189–96. 166. Meneghini LF, Schwartz SL, Rak ES, Harris A, Strange P. Improved glycemic control with insulin glargine (GLAR) vs pioglitazone (PIO) as add-on therapy in patients with type 2 diabetes (T2D) on sulfonylurea (SU) or metformin (MET) monotherapy. Poster (no 10-LB) presented at the ADA 65th Annual Scientific Sessions, San Diego, 10–14 June 2005. 167. Ryysy L, Yki-Järvinen H, Hanninen J, Hulme S, Kauppinen-Makelin R, Lahdenpera S, et al. Simplifying treat to target: the LANMET study. Diabetologia 2004;47:A271–2. 168. Raskin P, Park G, Zimmerman J. The effect of HOE 901 on glycemic control in type 2 diabetes. Diabetes 1998;47:A103. 169. Riddle MC, Rosenstock J, Gerich J. The treatto- target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080–6. 170. Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes RE, Dailey G. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 2006;29:554–9. 171. Haak T, Tiengo A, Draeger E, Suntum M, Waldhausl W. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 2005;7:56–64. 172. Hermansen K, Davies M, Derezinski T, Martinez RG, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006;29:1269–74. 173. Witthaus E, Stewart J, Bradley C. Improved psychological outcomes after initiation of insulin treatment in patients with Type II diabetes. Diabetologia 2000;43:A205. 174. Mannucci E, Monami M, Lamanna C, Gensini GF, Marchionni N. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. Diabetes Obes Metab 2008;10:1221–38. 175. Derezinski T, Davies M, Kim H, Clauson P. No correlation between weight gain and number of hypoglycaemic events in patients with type 2 diabetes treated with insulin detemir as compared to NPH insulin. Diabetologia 2006;49:94. 176. Rosenstock J, Davies M, Home PD, Larsen J, Tamer SC, Schernthaner G. Insulin detemir added to oral anti-diabetic drugs in type 2 diabetes provides glycemic control comparable to insulin glargine with less weight gain. Diabetes 2006;55:A132. 177. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52- week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008;51:408–16. 178. Montanana CF, Herrero CH, Fernandez MR. Less weight gain and hypoglycaemia with oncedaily insulin detemir than with NPH insulin in basal-bolus therapy of overweight type 2 diabetes patients: The PREDICTIVE-BMI trial. Diabet Med 2008;25:916–23. 179. Pan CY, Sinnassamy P, Chung KD, Kim KW, LEADStudy- Investigators-Group. Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients. Diabetes research and clinical practice 2007;76:111–18. 180. Philis-Tsimikas TA, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006;28:1569– 81. 181. Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716–30. 182. Hermansen K, Larsen J, Tamer SC, Mathieu C. More subjects achieve an HbA(1c) ≤ 7% without hypoglycaemia or weight gain when treated with insulin detemir in comparison with NPH insulin. Diabetologia 2007;50:S412. 183. Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T. Insulin detemir and insulin glargine: Similar time-action profiles in subjects with type 2 diabetes. Diabetes 2006;55:A76. 184. Kolendorf K, Kim H. Lower risk of hypoglycemia at each level of glycemic control when insulin detemir is added to oral agents compared to NPH insulin in patients with type 2 diabetes. Diabetes 2005;54:A121. 185. Wang XL, Lu JM, Pan CY, Mu YM, Dou JT, Ba JM, et al. Evaluation of the superiority of insulin glargine as basal insulin replacement by continuous glucose monitoring system. Diabetes Res Clin Pract 2007;76:30–6. 186. King AB, Armstrong DU. A randomized, crossover, double-blind comparison of insulin detemir and insulin glargine daily blood glucose profiles in subjects with type 2 diabetes. Diabetes 2008;57:A130. 187. European Medicines Agency. Avandia: European Public Assessment Report; 10 September 2008. URL: www.emea.europa.eu/humandocs/Humans/EPAR/ avandia/avandia.htm (accessed 13 May 2008). 188. European Medicines Agency. Actos: European Public Assessment Report; 16 February 2007. URL: www. emea.europa.eu/humandocs/Humans/EPAR/actos/ actos.htm (accessed 13 May 2008). 189. Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH. Rosiglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007;3:CD006063. 190. Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH. Pioglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev 2006;4:CD006060. 191. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279–89. 192. Erdmann E, Charbonnel B, Wilcox RG, Skene AM, Massi-Benedetti M, Yates J, et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 2007;30:2773–8. 193. Valentine WJ, Bottomley JM, Palmer AJ, Brandle M, Foos V, Williams R, et al. PROactive 06: costeffectiveness of pioglitazone in Type 2 diabetes in the UK. Diabet Med 2007;24:982–1002. 194. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457–71. 195. Drazen JM, Morrissey S, Curfman GD. Rosiglitazone: continued uncertainty about safety. N Engl J Med 2007;357:63–4. 196. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, et al. Rosiglitazone evaluated for cardiovascular outcomes: an interim analysis. N Engl J Med 2007;357:28–38. 197. Psaty BM, Furberg CD. The record on rosiglitazone and the risk of myocardial infarction. N Engl J Med 2007;357:67–9. 198. US Food and Drug Administration (FDA). GlaxoSmithKline Warning Letter. 25 March 2008. URL: www.fda.gov/foi/warning_letters/s6714c.htm (accessed 13 May 2008). 199. Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 2007;147:578–81. 200. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a metaanalysis. JAMA 2007;298:1189–95. 201. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007;370:1129–36. 202. Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008;299:1561–73. 203. Steg PG, Marre M. Does PERISCOPE provide a new perspective on diabetic treatment? JAMA 2008;299:1603–4. 204. Heartwire. VICTORY: “Reassuring” atherosclerosis/ metabolic data on rosiglitazone; 10 April 2008. URL: www.medscape.com/viewarticle/572836 (accessed 13 May 2008). 205. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a metaanalysis of randomized trials. JAMA 2007;298:1180– 8. 206. Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR. Use of thiazolidinediones and fracture risk. Arch Intern Med 2008;168:820–5. 207. Takeda Pharmaceuticals. Reobservation of an increased incidence of fractures in female patients who received long-term treatment with actos (pioglitazone HCL) tablets for type 2 diabetes Mellitus; March 2007. URL: www. fda.gov/medwatch/safety/2007/Actosmar0807.pdf (accessed 26 March 2009). 208. Rosen CJ. The rosiglitazone story: lessons from an FDA Advisory Committee meeting. N Engl J Med 2007;357:844–6. 209. US Food and Drug Administration (FDA). FDA Adds boxed warning for heart-related risks to anti-diabetes drug avandia; 14 November 2007. URL: www.fda.gov/bbs/ topics/NEWS/2007/NEW01743.html (accessed 13 May 2007). 210. Health Canada, GlaxoSmithKline. New restrictions on the use of AVANDIA®, AVANDAMET® and AVANDARYLTM (rosiglitazone products) due to cardiac safety concerns; 6 November 2007. URL: www.hc-sc. gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/medeff/ avandia_pc-cp_4_e.pdf (accessed 13 May 2008). 211. Health Canada. Scientific Advisory Committee On Metabolic And Endocrine Therapies (SC-MET); 15–16 November 2007. URL: www.hc-sc.gc.ca/dhp-mps/ alt_formats/hpfb-dgpsa/pdf/prodpharma/sacmet_a_ ccstme_o_2007–11–15_e.pdf (accessed 13 May 2008). 212. Glitazones in type 2 diabetes: an update. Drug Ther Bull 2008;46:25–9. 213. MTRAC (Midlands Therapeutics Review and Advisory Committee). Rosiglitazone (Avandia): verdict and summary; March 2008. URL: www.keele.ac.uk/ schools/pharm/MTRAC/ProductInfo/verdicts/R/ Rosiglitazone2.pdf (accessed 13 May 2008). 214. MTRAC (Midlands Therapeutics Review and Advisory Committee). Pioglitazone (Actos): verdict and summary; March 2008. URL: www.keele.ac.uk/ schools/pharm/MTRAC/ProductInfo/verdicts/P/ Pioglitazone2.pdf (accessed 13 May 2008). 215. The Scotsman. Doctors demand freeze on use of diabetes drug for heart patients. 8 May 2008. URL: http://news. scotsman.com/latestnews/Doctors-demand-freezeon- use.3953015.jp (accessed 13 May 2008). 216. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: update regarding the thiazolidinediones. Diabetologia 2008;51:8–11. 217. NPS RADAR. Rosiglitazone (Avandia) and rosiglitazone with metformin (Avandamet) for type 2 diabetes mellitus. December 2007. URL: www.npsradar.org.au/ npsradar/content/rosiglitazone.pdf (accessed 13 May 2008). 218. NPS RADAR. Pioglitazone (Actos) for type 2 diabetes mellitus. March 2008. www.npsradar.org.au/npsradar/ content/pioglitazone.pdf (accessed 13 May 2008). 219. National Prescribing Service Limited. New safety information about glitazones in NPS RADAR; 2007. URL: www.nps.org.au/resources/content/mediarel_ glitazones_tp.pdf (accessed 13 May 2008). 220. National Prescribing Service Ltd. Early use of insulin and oral antidiabetic drugs: Prescribing Practice Review No. 40; March 2008. URL: www.nps.org.au/site. php?content = /html/ppr.php&ppr = /resources/ Prescribing_Practice_Reviews/ppr40 (accessed 13 May 2008). 221. Dahabreh IJ. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone. Clin Trials 2008;5:116–20. 222. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096–105. 223. Berneis K, Rizzo M, Stettler C, Chappuis B, Braun M, Diem P, et al. Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type 2 diabetes. Exp Opin Pharmacother 2008;9:343–9. 224. Chappuis B, Braun M, Stettler C, Allemann S, Diem P, Lumb PJ, et al. Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study. Diabetes Metab Res Rev 2007;23:392–9. 225. Deeg MA, Buse JB, Goldberg RB, Kendall DM, Zagar AJ, Jacober SJ, et al. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2007;30:2458–64. 226. Norris SL, Carson S, Roberts C. Comparative effectiveness of pioglitazone and rosiglitazone in type 2 diabetes, prediabetes, and the metabolic syndrome: a meta-analysis. Curr Diab Rev 2007;3:127–40. 227. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129–39. 228. Endocrine Today. Rosiglitazone: one year later; 25 June 2008. URL: http://endocrinetoday.com/view. aspx?rid = 29105 (accessed 27 July 2008). 229. Shah BR, Juurlink DN, Austin PC, Mamdani MM. New use of rosiglitazone decreased following publication of a meta-analysis suggesting harm. Diabet Med 2008;25:871–4. 230. Gerstein HC, Miller ME, Byington RP, Goff DC, Jr, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545–59. 231. Berhanu P, Perez A, Yu S. Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy. Diabetes Obes Metab 2007;9:512–20. 232. Fernandez M, Triplitt C, Wajcberg E, Sriwijilkamol AA, Musi N, Cusi K, et al. Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms. Diabetes Care 2008;31:121–7. 233. Mattoo V, Eckland D, Widel M, Duran S, Fajardo C, Strand J, et al. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a sixmonth, randomized, double-blind, prospective, multicenter, parallel-group study. Clin Ther 2005;27:554–67. 234. Raz I, Stranks S, Filipczak R, Joshi P, Lertoft B, Rastam J, et al. Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study. Clin Ther 2005;27:1432–43. 235. Rosenstock J. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Prac 2002;56:251–7. 236. Scheen A, Charbonnel B. Reduced insulin requirements and improved glycemic control with pioglitazone in insulin-treated patients with type 2 diabetes: results from PROactive. Diabetes 2006;55:A134. 237. Shah PK, Mudahar S, Aroda V, Wilson J, Chao E, Chang A, et al. Weight gain and fat distribution with pioglitazone in patients with type 2 diabetes on insulin therapy. J Inves Med 2007;55 (Suppl. S):95. 238. Asnani S, Kunhiraman B, Jawa A, Akers D, Lumpkin D, Fonseca V. Pioglitazone restores endothelial function in patients with type 2 diabetes treated with insulin. Metab Syndr Relat Disord 2006;4:179– 84. 239. Davidson JA, Perez A, Zhang J, The P. Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study. Diabetes Obes Metab 2006;8:164–74. 240. Rosenblatt S, Cichy S, Sanes-Miller C. Long-term pioglitazone/insulin combination therapy improves glycemic control in type 2 diabetes. Diabetologia 2001;44:A233. 241. Davidson J, Vexiau P, Cucinotta D, Vaz J, Kawamori R. Biphasic insulin aspart 30: literature review of adverse events associated with treatment. Clin Ther 2005;27(Suppl. B):S75–88. 242. Raskin P, Braceras R, Schwartz S, Chaykin L, Chu PL, Wynne A. Over 75% of patients with type 2 diabetes reached target A1C by adding biphasic insulin aspart 70/30 to optimized metformin and pioglitazone treatment. Diabetes 2006;55:A131. 243. Raskin P, Braceras R, Schwartz S, Chaykin L, Chu PL, Wynne A. Over 75% of patients with type 2 diabetes reached HbA(1c) < 7% by adding biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment. Diabetologia 2006;49:487. 244. Ratner RE, Maggs D, Nielsen LL, Stonehouse AH, Poon T, Zhang B, et al. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformintreated patients with type 2 diabetes mellitus. Diabetes Obes Metab 2006;8:419–28. 245. Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006;8:436–47. 246. Dennett SL, Boye KS, Yurgin NR. The impact of body weight on patient utilities with or without type 2 diabetes: a review of the medical literature. Value Health 2008;11:478–86. 247. Bagust A, Beale S. Modelling EuroQol healthrelated utility values for diabetic complications from CODE-2 data. Health Econ 2005;14:217–30. 248. Coffey JT, Brandle M, Zhou H, Marriott D, Burke R, Tabaei BP, et al. Valuing health-related quality of life in diabetes. Diabetes Care 2002;25:2238–43. 249. Yu AP, Wu EQ, Birnbaum HG, Emani S, Fay M, Pohl G, et al. Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data. Curr Med Res Opin 2007;23:2157–69. 250. Edwards KL. Cost-effectiveness of intermediate or long-acting insulin versus Exenatide in type 2 diabetes mellitus patients not optimally controlled on dual oral diabetes medications. Pharmacy Practice 2006;4:129–33. 251. Shaya FT. Clinical and economic evaluation of exenatide for formulary decisions. J Med Econ 2007;10:529–37. 252. Minshall ME, Oglesby AK, Wintle ME, Valentine WJ, Roze S, Palmer AJ. Estimating the long-term cost-effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetes mellitus. Value Health 2008;11:22–33. 253. Ray JA, Boye KS, Yurgin N, Valentine WJ, Roze S, McKendrick J et al. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes. Curr Med Res Opin 2007;23:609–22. 254. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002;22:340–9. 255. Watkins JB, Minshall ME, Sullivan SD. Application of economic analyses in U.S. managed care formulary decisions: a private payer’s experience. J Manag Care Pharm 2006;12:726–35. 256. Scottish Medicines Consortium. Exenatide 5 or 10 micrograms, solution for injection, prefilled pen (Byetta); 9 July 2007. URL: www.scottishmedicines.org.uk/ smc/5206.html (accessed 25 March 2009). 257. Schwarz B, Gouveia M, Chen J, Nocea G, Jameson K, Cook J, et al. Cost-effectiveness of sitagliptinbased treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy. Diabetes Obes Metab 2008;10(Suppl. 1):43–55. 258. Minshall M, Charles M, Pandya B, Baran RW, Bron M. The cost-effectiveness of pioglitazone compared with sitagliptin: An economic evaluation using a validated economic model from a third party payer perspective in the USA. Value Health 2007;10:A259. 259. Celaya JM, Fon F, Ayala C, Antunez O, Garcia- Contreras F. A pharmacoeconomic evaluation for diabetes type 2 (DM 2) with inhibitors of dipeptidyl peptidase-4 (DPP-4) and thiazolidinediones (TZD) in monotherapy. Value Health 2007;10:A254. 260. Fon F, Celaya JM, Ayala C, Antunez O, Garcia- Contreras F. A pharmacoeconomic evaluation for diabetes type 2 (DM 2) patients with inhibitors of dipeptidyl peptidase-4 (DPP-4) and thiazolidinediones (TZD) as add-on therapy. Value Health 2007;10:A254. 261. Scottish Medicines Consortium. Vildagliptin (Galvus); 7 April 2008. URL: www.scottishmedicines.org.uk/ smc/5473.html (accessed 24 March 2009). 262. Scottish Medicines Consortium. Sitagliptin 100mg tablets (Januvia); 8 October 2007. URL: www. scottishmedicines.org.uk/smc/5358.html (accessed 24 March 2009). 263. Brandle M, Azoulay M, Greiner RA. Costeffectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland. Int J Clin Pharmacol Ther 2007;45:203–20. 264. Maxion-Bergemann S, Huppertz E, Jacobs LD, Muller E, Walleser S. Improved glycemic control with decreased hypoglycemia prevents long-term complications in type 2 diabetes patients: long-term simulation analysis using the “diabetes mellitus model”. Int J Clin Pharmacol Ther 2005;43:271–81. 265. Grima DT, Thompson MF, Sauriol L. Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada. Pharmacoeconomics 2007;25:253–66. 266. Yki-Järvinen H, Haring HU, Johnson E, Robert- Engels C, Nguyen H, Zeger S, et al. The relationship between glycemic control and Hypoglycemia using insulin glargine-versus NPH insulin: a metaregression analysis in type 2 diabetes. Diabetes 2003;52:A149–150. 267. McEwan P, Tetlow AP, Holmes P, Poole CD, Currie CJ. The relative cost effectiveness of insulin glargine versus NPH insulin in the UK in people with type 2 diabetes. Value Health 2006;9:A227–8. 268. Currie CJ, Morgan CL, Poole CD, Sharplin P, Lammert M, McEwan P. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006;22:1523–34. 269. McEwan P, Mehin N, Ap T, Sharplin P. The relative cost effectiveness of insulin glargine versus nph insulin using UK real life data in patients with type 2 diabetes mellitus. Value Health 2007;10:A64–5. 270. McEwan P, Poole CD, Tetlow T, Holmes P, Currie CJ. Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK. Curr Med Res Opin 2007;23:S21–31. 271. Valentine WJ, Erny-Albrecht KM, Ray JA, Roze S, Cobden D, Palmer AJ. Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: A modeling study of costeffectiveness in the United States. Advances Ther 2007;24:273–90. 272. Dornhorst A, Luddeke HJ, Sreenan S, Kozlovski P, Hansen JB, Looij BJ, et al. Insulin detemir improves glycaemic control without weight gain in insulinnaive patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study. Int J Clin Pract 2008;62:659–65. 273. Poole CD, Tetlow T, McEwan P, Holmes P, Currie CJ. The prescription cost of managing people with type 1 and type 2 diabetes following initiation of treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis. Curr Med Res Opin 2007;23:S41–8. 274. Valentine WJ, Palmer AJ, Erny-Albrecht KM, Ray JA, Cobden D, Foos V, et al. Cost-effectiveness of basal insulin from a US health system perspective: Comparative analyses of detemir, glargine, and NPH. Advances Ther 2006;23:191–207. 275. Ray JA, Valentine WJ, Roze S, Nicklasson L, Cobden D, Raskin P, et al. Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US. Diabetes Obes Metab 2007;9:103–13. 276. Goodall G, Jendle JH, Valentine WJ, Munro V, Brandt AB, Ray JA, et al. Biphasic insulin aspart 70/30 vs. insulin glargine in insulin naive type 2 diabetes patients: modelling the long-term health economic implications in a Swedish setting. Int J Clin Pract 2008;62:869–76. 277. Lechleitner M, Roden M, Haehling E, Mueller M. Insulin glargine in combination with oral antidiabetic drugs as a cost-equivalent alternative to conventional Insulin therapy in type 2 diabetes mellitus. Wien Klin Wochenschr 2005;117:593–8. 278. Janka HU, Hogy B. Economic evaluation of the treatment of type 2 diabetes with insulin glargine based on the LAPTOP trial. Eur J Health Econ 2008;9:165–70. 279. Thompson M, Sauriol L, Grima D. Health economic evaluation of insulin glargine for the treatment of type-1 and type-2 diabetes. Value Health 2005;8:A163. 280. Smith I, Palmer AJ, Roze S, Kennedy-Martin T. Cost-effectiveness analysis of insulin detemir compared to NPH insulin in patients with type- 2 diabetes in the United Kingdom. Value Health 2004;7:735–6. 281. Valentine WJ, Cobden D, Palmer AJ, Wagner S, Roze S. Therapy class conversion in patients with type 2 diabetes: Economic evaluation of insulin detemir and NPH. Value Health 2006;9:A230. 282. Valentine WJ, Goodall G, Aagren M, Nielsen S, Kotchie R. Evaluating the long-term clinical and economic implications of converting type 2 diabetes patients to insulin detemir (± oral hypoglycemic agents) from insulin glargine based regimens in Germany; Data from the predictive study. Value Health 2007;10:A263–4. 283. Valentine W, Cobden D, Palmer A, Roze S. Modeling the cost-utility of reduced hypoglycemia and weight gain among type 2 diabetes patients newly initiated on basal insulin: a case study of detemir and NPH. Value Health 2006;9:A36. 284. Palmer AJ, Cobden D, Valentine WJ, Wagner S, Roze S. Economic evaluation of initiating insulin detemir among type 2 diabetes patients receiving oral medication. Value Health 2006;9:A230. 285. Palmer A, Roze S, Nicklasson L, Allen E, Garber A. Estimating the cost-effectiveness in the US of biphasic insulin aspart 70/30 vs. insulin glargine over the INITIATE trial patient’s estimated lifespan. Diabetes 2005;54:A613. 286. Clarke PM, Gray AM, Briggs A, Farmer AJ, Fenn P, Stevens RJ, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004;47:1747–59. 287. Mueller E, Maxion-Bergemann S, Gultyaev D, Walzer S, Freemantle N, Mathieu C, et al. Development and validation of the Economic Assessment of Glycemic Control and Long-Term Effects of diabetes (EAGLE) model. Diabetes Technol Ther 2006;8:219–36. 288. Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(Suppl. 1):5–26. 289. Rubino A, McQuay LJ, Kvasz M, Tennis P. Population-based study of time to insulin after failure of oral antidiabetic therapy in type 2 diabetes in the UK; 2006. URL: www.rtihs.org/request/index. cfm?fuseaction = display&PID = 7159 (accessed 27 July 2008). 290. British Medical Association and Royal Pharmaceutical Society of Great Britain. British national formulary. No. 56, September 2008. London: BMA and RPS; 2008. 291. Personal Social Services Research Unit (PSSRU). Unit Costs of Health and Social Care; 2007. Compiled by Curtiss, L. URL: www.pssru.ac.uk/uc/ uc2007contents.htm (accessed 27 May 2008). 292. Matza LS, Boye KS, Yurgin N, Brewster-Jordan J, Mannix S, Shorr JM, et al. Utilities and disutilities for type 2 diabetes treatment-related attributes. Qual Life Res 2007;16:1251–65. 293. National Insitute for Health and Clinical Excellence (NICE). Obesity: the prevention, identification, assessment and management of overweight and obesity in adults and children. Clinical Guideline CG43; December 2006. URL: www.nice.org.uk/Guidance/CG43 (accessed 23 March 2009). 294. Dolan P, Gudex C, Kind P, Williams A. A social tariff for EuroQoL: results from a UK General Population Survey. Centre for Health Economics discussion paper 138, University of York; 1995. URL: www. york.ac.uk/inst/che/pdf/DP138.pdf (accessed 23 June 2009).
URI:	http://wrap.warwick.ac.uk/id/eprint/44115

Request changes to a record

Actions (login required)

View Item